Marcus Mall

Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele

Peter G. Middleton, Marcus Mall, Pavel Dřevı́nek et al. · New England Journal of Medicine · 2019 · 2.1K citations · Full text

Life Sciences, Pharmacology, Pharmacotherapy +16

SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19

Julian Braun, Lucie Loyal, Marco Frentsch et al. · Nature · 2020 · 1.4K citations · Full text

Life Sciences, Immunology, Infectious Diseases +8

Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial

Harry Heijerman, Edward F. McKone, D.G. Downey et al. · The Lancet · 2019 · 1.4K citations · Full text

Life Sciences, Genetics, Pharmacology +14

Increased airway epithelial Na+ absorption produces cystic fibrosis-like lung disease in mice

Marcus Mall, Barbara R. Grubb, Jack R. Harkema et al. · Nature Medicine · 2004 · 899 citations

Veterinary Medicine, Cell Biology, Pathobiology +12

VX-445–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles

D. Keating, Gautham Marigowda, Lucy Burr et al. · New England Journal of Medicine · 2018 · 727 citations · Full text

Pharmacy, Molecular Genetics, Pharmacotherapy +13